Singh Prince, Harris Peter C, Sas David J, Lieske John C
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
Division of Molecular Biology and Biochemistry, Mayo Clinic, Rochester, MN, USA.
Nat Rev Nephrol. 2022 Apr;18(4):224-240. doi: 10.1038/s41581-021-00513-4. Epub 2021 Dec 14.
Kidney stones (also known as urinary stones or nephrolithiasis) are highly prevalent, affecting approximately 10% of adults worldwide, and the incidence of stone disease is increasing. Kidney stone formation results from an imbalance of inhibitors and promoters of crystallization, and calcium-containing calculi account for over 80% of stones. In most patients, the underlying aetiology is thought to be multifactorial, with environmental, dietary, hormonal and genetic components. The advent of high-throughput sequencing techniques has enabled a monogenic cause of kidney stones to be identified in up to 30% of children and 10% of adults who form stones, with ~35 different genes implicated. In addition, genome-wide association studies have implicated a series of genes involved in renal tubular handling of lithogenic substrates and of inhibitors of crystallization in stone disease in the general population. Such findings will likely lead to the identification of additional treatment targets involving underlying enzymatic or protein defects, including but not limited to those that alter urinary biochemistry.
肾结石(也称为尿石症或肾石病)极为常见,全球约10%的成年人受其影响,且结石病的发病率正在上升。肾结石的形成是由于结晶抑制剂和促进剂失衡所致,含钙结石占结石的80%以上。在大多数患者中,潜在病因被认为是多因素的,包括环境、饮食、激素和遗传因素。高通量测序技术的出现使得在高达30%的患结石儿童和10%的患结石成年人中确定了单基因导致的肾结石病因,涉及约35种不同基因。此外,全基因组关联研究表明,普通人群中一系列参与肾小管处理致石底物和结晶抑制剂的基因与结石病有关。这些发现可能会导致确定更多涉及潜在酶或蛋白质缺陷的治疗靶点,包括但不限于那些改变尿液生物化学的靶点。